{"id":394350,"date":"2022-08-10T22:35:03","date_gmt":"2022-08-10T20:35:03","guid":{"rendered":"https:\/\/innovationorigins.com\/?p=394350"},"modified":"2022-08-10T22:35:03","modified_gmt":"2022-08-10T20:35:03","slug":"chinese-grandpharma-supports-xeltis-with-a-e15m-investment-as-part-of-a-new-financing-round","status":"publish","type":"post","link":"https:\/\/ioplus.nl\/archive\/en\/chinese-grandpharma-supports-xeltis-with-a-e15m-investment-as-part-of-a-new-financing-round\/","title":{"rendered":"Chinese Grand Pharma supports Xeltis with a \u20ac15M investment as part of a new financing round"},"content":{"rendered":"\n

As many Western organizations are increasingly hesitant in their relations with Chinese partners, Eindhoven-based Xeltis is striking a big deal. For 15 million euros, the Grand Pharmaceutical Group receives not only shares, but also commercial and development rights. For Xeltis, it is the first commercial deal in its existence.<\/p>\n\n\n\n

Xeltis<\/a>, a medtech company developing polymer-based restorative cardiovascular devices gets financial support from the Chinese company, Grand Pharmaceutical Group Ltd<\/a>. The Chinese have committed to invest \u20ac15 million in equity and license fees, as a cornerstone funding for its ongoing Series D2 financing round.<\/p>\n\n\n\n

The Grand Pharma commitment comprises an equity investment and product license, representing Xeltis\u2019 first commercial deal and its first funding from an Asian company. The agreement, which focuses mainly on Xeltis\u2019 restorative hemodialysis access device aXess, also involves other new products in the field of hemodialysis developed under the same technology platform. Grand Pharma will also have exclusive rights of development, production and commercialization, and pre-emptive negotiation right for Xeltis\u2019 products developed in other indications in the Greater China region.<\/p>\n\n\n

<\/a>
<\/div><\/div>
Read more on Xeltis, a former winner of Innovation Origins’ Gerard & Anton Award<\/div>
Your Sneak Preview of the Future<\/div><\/div><\/div>\n\n\n

\u201cGrand Pharma\u2019s commitment to invest in Xeltis brings global validation of aXess\u2019 commercial potential from one of the largest Chinese life sciences companies, from the country with the most significant need of hemodialysis access globally,\u201d said Eliane Schutte, Xeltis CEO. \u201cIt confirms the strength of our technology platform and clinical evidence to date, and supports our goal of providing potentially more durable, transformative restorative devices for patients worldwide.\u201d<\/p>\n\n\n\n

Schutte says aXess is a first-of-its-kind restorative cardiovascular access graft for patients with chronic kidney disease (CKD) requiring hemodialysis. China has the most significant number of CKD patients in the world, accounting for about 130 million people, of which around 580,000 are currently on hemodialysis. The number of people on hemodialysis in China is projected to increase by 15 percent in the next five years. <\/p>\n\n\n\n

\u201cGrand Pharma is building an interventional diagnosis and treatment platform for cardiovascular and cerebrovascular diseases in China,\u201d Grand Pharmaceutical Group CEO, Frank Zhou added. “Xeltis\u2019 aXess device would represent an excellent addition to the scope of our broad portfolio and expected to bring significant clinical impact in China.”<\/p>\n\n\n\n

The aXess graft enables early puncturing, or the initiation of dialysis, working like some of the currently available ePTFE synthetic hemodialysis access grafts. In addition, it is designed to turn into a patient\u2019s own living blood vessel, like an arteriovenous fistula. Once implanted, its biocompatible, porous micro- structure gets naturally colonized by the patient\u2019s own tissue, which over time takes over functionality before the original device absorbs in the body. This process is called endogenous tissue restoration (ETR).<\/p>\n","protected":false},"excerpt":{"rendered":"

As many Western organizations are increasingly hesitant in their relations with Chinese partners, Eindhoven-based Xeltis is striking a big deal. For 15 million euros, the Grand Pharmaceutical Group receives not only shares, but also commercial and development rights. For Xeltis, it is the first commercial deal in its existence. Xeltis, a medtech company developing polymer-based […]<\/p>\n","protected":false},"author":1568,"featured_media":515737,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[34665],"tags":[8098,72698,53380,10413],"location":[6763],"article_type":[36684],"serie":[],"archives":[],"internal_archives":[],"reboot-archive":[],"class_list":["post-394350","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-china-en","tag-grandpharma","tag-medtechbrabant","tag-xeltis","location-netherlands","article_type-news"],"blocksy_meta":[],"acf":{"subtitle":"The deal will focus on the restorative hemodialysis access device from Xeltis called aXess and allow the startup to roll out additional novel hemodialysis products.","text_display_homepage":false},"author_meta":{"display_name":"Bart Brouwers","author_link":"https:\/\/ioplus.nl\/archive\/author\/brewbart\/"},"featured_img":"https:\/\/ioplus.nl\/archive\/wp-content\/uploads\/2022\/08\/GrandPharm.jpeg","coauthors":[],"tax_additional":{"categories":{"linked":["Health<\/a>"],"unlinked":["Health<\/span>"]},"tags":{"linked":["china<\/a>","GrandPharma<\/a>","MedTechBrabant<\/a>","Xeltis<\/a>"],"unlinked":["china<\/span>","GrandPharma<\/span>","MedTechBrabant<\/span>","Xeltis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on August 10, 2022","modified":"Updated on August 10, 2022"},"absolute_dates_time":{"created":"Posted on August 10, 2022 10:35 pm","modified":"Updated on August 10, 2022 10:35 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/394350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/users\/1568"}],"replies":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/comments?post=394350"}],"version-history":[{"count":0,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/394350\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media\/515737"}],"wp:attachment":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media?parent=394350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/categories?post=394350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/tags?post=394350"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/location?post=394350"},{"taxonomy":"article_type","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/article_type?post=394350"},{"taxonomy":"serie","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/serie?post=394350"},{"taxonomy":"archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/archives?post=394350"},{"taxonomy":"internal_archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/internal_archives?post=394350"},{"taxonomy":"reboot-archive","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/reboot-archive?post=394350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}